-transparent.png){kind=logo}
The effect of doxazosin, a selective alpha-1 adrenergic inhibitor, on hemostasis was investigated in 9 cynomolgus monkeys. During 12 weeks of doxazosin treatment (1 mg/kg per day), serum lipids, lipoprotein cholesterols, blood coagulation, platelet aggregation and template bleeding times were measured and compared with predrug values. In addition, platelet adhesion to cultured human umbilical vein endothelial cells (HUVEC) in the presence or absence of doxazosin was evaluated. Platelet aggregation was also determined in monkeys following chronic oral exposure to aspirin (162 mg/day). Doxazosin administration was associated with significant reductions in serum total cholesterol (TC) (-16%) and low density lipoprotein cholesterol (LDL-C) (-23%), while high density lipoprotein cholesterol (HDL-C) levels increased 66%. Doxazosin did not alter any parameters of blood coagulation measured; however, bleeding times were increased significantly (33%) in doxazosin-treated animals. Although collagen-stimulated platelet aggregation was not influenced by either chronic doxazosin or aspirin treatment, the maximal extent of ADP-stimulated platelet aggregation was significantly reduced (-26% and -18%, respectively) compared with the control monkeys. Platelets from untreated control animals displayed reductions in the extent of ADP-stimulated aggregation of 13% and 23%, respectively, when incubated in vitro with 200 and 300 micrograms/ml of doxazosin. Additionally, the decrease in aggregation response of platelets obtained from doxazosin-treated monkeys was accompanied by a rapid reversal of platelet aggregation. Adhesion to HUVEC by platelets isolated from doxazosin-treated animals was significantly decreased; however, adhesion was not altered when platelets from untreated control animals were incubated with HUVEC in the presence of doxazosin. Thus, the ex vivo and in vitro studies reported in this communication suggest that doxazosin administration to nonhuman primates is associated with beneficial alterations in plasma lipids, platelet aggregation, bleeding times and platelet adhesion to endothelial cells, parameters which are thought to influence risk of cardiovascular disease in both animals and humans.
E J Weiner, and
A F Stucchi, and
T L Foxall, and
G T Shwaery, and
S Yoganathan, and
R J Nicolosi
April 1990,
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
E J Weiner, and
A F Stucchi, and
T L Foxall, and
G T Shwaery, and
S Yoganathan, and
R J Nicolosi
November 1996,
Sports medicine (Auckland, N.Z.),
E J Weiner, and
A F Stucchi, and
T L Foxall, and
G T Shwaery, and
S Yoganathan, and
R J Nicolosi
May 2002,
Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials,
E J Weiner, and
A F Stucchi, and
T L Foxall, and
G T Shwaery, and
S Yoganathan, and
R J Nicolosi
September 2012,
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis,
E J Weiner, and
A F Stucchi, and
T L Foxall, and
G T Shwaery, and
S Yoganathan, and
R J Nicolosi
August 2007,
Clinical and experimental pharmacology & physiology,
E J Weiner, and
A F Stucchi, and
T L Foxall, and
G T Shwaery, and
S Yoganathan, and
R J Nicolosi
February 2003,
Biological & pharmaceutical bulletin,
E J Weiner, and
A F Stucchi, and
T L Foxall, and
G T Shwaery, and
S Yoganathan, and
R J Nicolosi
September 1998,
Toxicology letters,
E J Weiner, and
A F Stucchi, and
T L Foxall, and
G T Shwaery, and
S Yoganathan, and
R J Nicolosi
January 1967,
New Istanbul contribution to clinical science,
E J Weiner, and
A F Stucchi, and
T L Foxall, and
G T Shwaery, and
S Yoganathan, and
R J Nicolosi
January 2023,
Advances in pharmacological and pharmaceutical sciences,
E J Weiner, and
A F Stucchi, and
T L Foxall, and
G T Shwaery, and
S Yoganathan, and
R J Nicolosi
October 2018,
Zhongguo shi yan xue ye xue za zhi,
